MHRA launches medicines manufacturing support service in UK
The UK medicines regulator is rolling out a new support service aimed at helping developers tackle regulatory and quality issues earlier in the creation of advanced manufacturing technologies. The initiative, called AdvanceGxP, is designed to speed patient access to innovative treatments while reinforcing the UK's life sciences manufacturing base.
Highlights
- MHRA secured funding from the Office for Life Sciences to develop and test AdvanceGxP, announced at the DIA-MHRA Global Summit on 17 November 2026.
- AdvanceGxP targets advanced manufacturing technologies—like personalised treatments, AI, robotics, and space manufacturing—with early regulatory guidance to prevent costly delays and support scaling.
- The service aligns with the UK Life Sciences Sector Plan, aims to make the UK more competitive for investment, and will initially have limited capacity during pilot rollout.
Funding-backed rollout for advanced manufacturing support
As reported by GOV.UK, the Medicines and Healthcare products Regulatory Agency has secured funding from the Office for Life Sciences to develop and test AdvanceGxP, a service focused initially on advanced manufacturing technologies. Science, Innovation and Investment Minister Chris McDonald announced the programme in a closing speech at the inaugural DIA-MHRA Global Summit in London on 17 November 2026, during London Life Sciences Week.The service is being developed to give companies earlier practical help on regulatory and quality questions linked to new ways of making medicines. These include personalised treatments made at or near hospitals and clinics, manufacturing in space, and the use of AI, robotics and automation.
MHRA Chief Executive Lawrence Tallon said earlier support can help developers solve problems before they create delays, support investment decisions and make it easier for promising approaches to grow and scale in the UK. The agency said the funding will allow it to recruit a specialist team and design how organisations will access the service, which projects will be prioritised and how the offering will connect with existing MHRA support.
Life sciences and industrial strategy impact
AdvanceGxP is intended to reduce the risk of avoidable redesigns and delays later in development, while also supporting more sustainable manufacturing approaches. The MHRA says the model is meant to strengthen patient access to new treatments and support the government's Life Sciences Sector Plan and broader Industrial Strategy.Office for Life Sciences Director Kenan Poleo said the UK's regulatory environment can serve as a competitive advantage as global competition for life sciences investment intensifies. He said the new service should give companies more confidence to develop and manufacture transformative technologies in the UK.
Initial capacity will be limited while the approach is developed and tested, with that process helping determine whether the service can operate sustainably and broaden over time. The initiative also sits alongside the MHRA Strategy to 2030, which sets out a wider push for earlier engagement with innovators and more coordinated support across the health and life sciences system.
As highlighted earlier, Australia-UK innovation cooperation under their free trade agreement set priorities including life sciences and advanced manufacturing.